论文部分内容阅读
目的探索布美他尼在抑制肿瘤细胞增殖中的应用。方法采用免疫印迹杂交技术,验证不同肿瘤细胞中钠钾氯协同转运蛋白1(NKCC1)的表达情况;运用CCK-8法,测定布美他尼对不同肿瘤细胞的IC50值。结果肺癌细胞系(A549)、结直肠癌细胞系(HCT116)中靶蛋白NKCC1表达量显著高于慢性粒细胞白血病细胞系(K562)、食管癌细胞系(Eca109)、宫颈癌细胞系(He La)、T淋巴细胞白血病细胞系(Jurkat)和乳腺癌细胞系(MCF7);布美他尼对A549、HCT116的IC50值明显低于K562、Eca109、He La、Jurkat和MCF7,且其抑制率与靶蛋白NKCC1的表达量呈正相关。结论布美他尼能抑制肿瘤细胞增殖,NKCC1可作为潜在的抗肿瘤药物作用靶点。
Objective To explore the application of bumetanide in the inhibition of tumor cell proliferation. Methods The expression of sodium-potassium chloride co-transporter 1 (NKCC1) in different tumor cells was verified by Western blotting. The IC50 value of bumetanide to different tumor cells was determined by CCK-8 assay. Results The expression of NKCC1 in lung cancer cell line (A549) and colorectal cancer cell line (HCT116) was significantly higher than that in chronic myeloid leukemia cell line (K562), esophageal cancer cell line (Eca109), cervical cancer cell line He La ), Jurkat cells and breast cancer cell lines (MCF7). The IC50 of bumetanide to A549 and HCT116 was significantly lower than that of K562, Eca109, He La, Jurkat and MCF7, The expression of target protein NKCC1 was positively correlated. Conclusion Bumetanide can inhibit tumor cell proliferation, NKCC1 can be used as a potential anti-tumor drug target.